+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

More effective positioning of capecitabine for advanced and metastatic breast cancer



More effective positioning of capecitabine for advanced and metastatic breast cancer



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(4): 649-653



We investigated 30 patients with advanced and metastatic breast cancer who underwent capecitabine therapy in our department from July, 2004 to April, 2009. Patients' backgrounds: 35-82 years of age (median, 62 years of age). Performance status (PS): 0 approximately 1 in 21 cases, PS:2 in 7 cases and PS:3 in 2 cases. 63% of patients were positive ER and/or PgR, and 33. 3% were positive HER2. Of these patients, 17 had bone, 15 lymph node, 13 lung, 7 liver, and 4 skin metastasis. The capecitabine response in these patients was evaluated as follows: partial response (PR) in 9, stable disease (SD)in 6, long SD in 4, and progressive disease(PD)in 11, indicating a response rate(RR)of 30% and a clinical benefit rate (CBR) of 43. 3%. In comparison with after third-line treatment, capecitabine proved more effective as first or second-line treatment. Interestingly, the capecitabine response in HER2 negative-expressing patients, especially in HR(+)/HER2(-)subgroup, was significantly better than that in HER2-over-expressing patients. The soft tissue lesions(primary tumor and metastasis of skin and lymph nodes)showed a significantly better response to capecitabine treatment than other metastases such as lung, liver and bone. There was a significant difference in the response rate between soft tissue metastasis (lymph nodes, skin and primary tumor)and other types of metastasis (lung, liver, and bone). Finally, it was suggested that use of capecitabine in upfront line for HER2-negative expressing cases or soft tissue metastatic cases contributed to the prolongation of time to treatment failure(TTF)and overall survival.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 054463441

Download citation: RISBibTeXText

PMID: 20414020


Related references

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study. Cancer 122(20): 3119-3126, 2016

Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 11(4): 325-335, 2006

Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer 17(4): 233-240, 2011

Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncologica 43(2): 186-189, 2004

Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 14(5): 368-374, 2005

Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. Oncology 70(4): 294-300, 2006

Combining Fulvestrant with Low-Dose Capecitabine is Effective and Tolerable in Woman with Metastatic Breast Cancer. Journal of Nippon Medical School 83(2): 81-86, 2017

Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(11): 2165-2168, 2011

Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. Japanese Journal of Clinical Oncology 40(3): 188-193, 2010

Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer. Breast Care 5(3): 158-162, 2010

Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clinical Breast Cancer 6(6): 518-524, 2006

Pilot study of capecitabine combined with celecoxib (CapCel) for the treatment of far advanced metastatic breast cancer (MBC) patients (pts). Journal of Clinical Oncology 24(18_suppl): 10680-10680, 2016

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. British Journal of Cancer 90(9): 1740-1746, 2004

Clinical effect and positioning of capecitabine for metastatic breast carcinoma. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(8): 1315-1318, 2008

Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. 2007